

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 October 2022 (27.10.2022)



(10) International Publication Number
WO 2022/224212 A1

(51) International Patent Classification:

C07D 257/04 (2006.01) A61P 35/00 (2006.01)
A61P 1/00 (2006.01) A61P 37/08 (2006.01)
A61P 9/00 (2006.01) A61K 31/50 (2006.01)
A61P 9/12 (2006.01) A61K 31/4439 (2006.01)
A61P 29/00 (2006.01) A61K 31/41 (2006.01)

(21) International Application Number:

PCT/IB2022/053772

(22) International Filing Date:

22 April 2022 (22.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2105846.6 23 April 2021 (23.04.2021) GB

(71) Applicant: **HEPTARES THERAPEUTICS LIMITED**

[GB/GB]; Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB).

(72) Inventors: **CONGREVE, Miles Stuart**; c/o Heptares

Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **SWAIN, Nigel Alan**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **BROWN, Giles Albert**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **WHITEHURST, Benjamin**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB). **FLANAGAN, Neil John**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: GPR35 AGONIST COMPOUNDS



(57) Abstract: The disclosures herein relate to novel compounds of formula (1): (1) and salts and any tautomers thereof, wherein X, R¹ and R² are defined herein, and their use 5 in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR35 receptors.



WO 2022/224212 A1